Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$1.50 USD
-0.14 (-8.54%)
Updated May 28, 2024 04:00 PM ET
After-Market: $1.50 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Nektar Therapeutics [NKTR]
Reports for Purchase
Showing records 181 - 200 ( 394 total )
Company: Nektar Therapeutics
Industry: Medical - Drugs
PAINWeek Conference Abstracts Reveal New Withdrawal Data on NKTR-181
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
With Cash in Hand, Nektar Looks for More in Q4
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Nektar Therapeutics
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Nektar Therapeutics
Industry: Medical - Drugs
Autoimmune Partnership Reached with Lilly on NKTR-358; PT to $32.50
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Nektar Therapeutics
Industry: Medical - Drugs
NKTR-181 Demonstrates a Low Potential for Abuse; Receptive FDA?
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Nektar Therapeutics
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Early Efficacy and Continued Safety of NKTR-214 at ASCO ?17
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Nektar Therapeutics
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Nektar Therapeutics
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Nektar Therapeutics
Industry: Medical - Drugs
Gottlieb?s Remarks Suggest More Leeway For NKTR-181''s Early Approval
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Nektar Therapeutics
Industry: Medical - Drugs
Research Collaboration with NKTR-214 and Five Takeda Oncology Compounds
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Nektar Therapeutics
Industry: Medical - Drugs
2017 Guidance Confirmed; Potential Partnerships of Three Assets in 2017
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Nektar Therapeutics
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.